HRP20180141T1 - 5-benzilizokinolinski derivati za liječenje srčanožilnih bolesti - Google Patents

5-benzilizokinolinski derivati za liječenje srčanožilnih bolesti Download PDF

Info

Publication number
HRP20180141T1
HRP20180141T1 HRP20180141TT HRP20180141T HRP20180141T1 HR P20180141 T1 HRP20180141 T1 HR P20180141T1 HR P20180141T T HRP20180141T T HR P20180141TT HR P20180141 T HRP20180141 T HR P20180141T HR P20180141 T1 HRP20180141 T1 HR P20180141T1
Authority
HR
Croatia
Prior art keywords
group
pharmaceutically acceptable
hydrates
addition salts
acceptable acid
Prior art date
Application number
HRP20180141TT
Other languages
English (en)
Croatian (hr)
Inventor
Stefano Chimenti
Christine Courchay
Aimée Dessinges
Françoise GELLIBERT
Bertrand Goument
Marc KONNERT
Jean-Louis Peglion
Christophe Poitevin
Jean-Paul Vilaine
Nicole Villeneuve
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of HRP20180141T1 publication Critical patent/HRP20180141T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HRP20180141TT 2014-02-21 2015-02-20 5-benzilizokinolinski derivati za liječenje srčanožilnih bolesti HRP20180141T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1451389A FR3017868A1 (fr) 2014-02-21 2014-02-21 Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP15709289.1A EP3107900B1 (fr) 2014-02-21 2015-02-20 Dérivés de 5-benzylisoquinoléine pour le traitement de maladies cardiovasculaires
PCT/FR2015/050415 WO2015124877A1 (fr) 2014-02-21 2015-02-20 Dérivés de 5-benzylisoquinoléine pour le traitement de maladies cardiovasculaires

Publications (1)

Publication Number Publication Date
HRP20180141T1 true HRP20180141T1 (hr) 2018-03-09

Family

ID=50424640

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180141TT HRP20180141T1 (hr) 2014-02-21 2015-02-20 5-benzilizokinolinski derivati za liječenje srčanožilnih bolesti

Country Status (37)

Country Link
US (1) US9809553B2 (cg-RX-API-DMAC7.html)
EP (1) EP3107900B1 (cg-RX-API-DMAC7.html)
JP (1) JP6491226B2 (cg-RX-API-DMAC7.html)
KR (1) KR102251198B1 (cg-RX-API-DMAC7.html)
CN (1) CN105980361B (cg-RX-API-DMAC7.html)
AR (1) AR099493A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015220659B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016017679B1 (cg-RX-API-DMAC7.html)
CA (1) CA2938344C (cg-RX-API-DMAC7.html)
CL (1) CL2016002089A1 (cg-RX-API-DMAC7.html)
CY (1) CY1120034T1 (cg-RX-API-DMAC7.html)
DK (1) DK3107900T3 (cg-RX-API-DMAC7.html)
EA (1) EA030617B1 (cg-RX-API-DMAC7.html)
ES (1) ES2659885T3 (cg-RX-API-DMAC7.html)
FR (1) FR3017868A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20180141T1 (cg-RX-API-DMAC7.html)
HU (1) HUE038337T2 (cg-RX-API-DMAC7.html)
IL (1) IL246721B (cg-RX-API-DMAC7.html)
JO (1) JO3372B1 (cg-RX-API-DMAC7.html)
LT (1) LT3107900T (cg-RX-API-DMAC7.html)
MA (1) MA39207A1 (cg-RX-API-DMAC7.html)
ME (1) ME02863B (cg-RX-API-DMAC7.html)
MX (1) MX363301B (cg-RX-API-DMAC7.html)
MY (1) MY178745A (cg-RX-API-DMAC7.html)
NO (1) NO3107900T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ722513A (cg-RX-API-DMAC7.html)
PL (1) PL3107900T3 (cg-RX-API-DMAC7.html)
PT (1) PT3107900T (cg-RX-API-DMAC7.html)
RS (1) RS56766B1 (cg-RX-API-DMAC7.html)
RU (1) RU2679621C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201605662TA (cg-RX-API-DMAC7.html)
SI (1) SI3107900T1 (cg-RX-API-DMAC7.html)
TW (1) TWI547484B (cg-RX-API-DMAC7.html)
UA (1) UA117953C2 (cg-RX-API-DMAC7.html)
UY (1) UY35997A (cg-RX-API-DMAC7.html)
WO (1) WO2015124877A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201604976B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640496B2 (en) * 2016-06-17 2020-05-05 Daewoong Pharmaceutical Co., Ltd. Method for producing diphenylmethane derivative
US12338238B2 (en) 2018-06-07 2025-06-24 Disarm Therapeutics, Inc. Inhibitors of SARM1
JP2021529830A (ja) * 2018-07-02 2021-11-04 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) ラクテート増強化合物及びその使用
US11248004B2 (en) 2018-11-06 2022-02-15 Cervello Therapeutics, Llc. Substituted isoquinolines as rock kinase inhibitors
ES2991902T3 (es) 2018-11-06 2024-12-05 Cervello Therapeutics LLC Inhibidores de la cinasa rock
BR112021017354A2 (pt) 2019-03-01 2021-11-16 Beijing Tide Pharmaceutical Co Ltd Método para o tratamento de doença hepática adiposa e/ou esteatoepatite
JP7699820B2 (ja) 2019-03-22 2025-06-30 サニオナ エー/エス 新規カリウムチャネル阻害剤
EP4051680B1 (en) 2019-10-30 2025-09-03 Biogen MA Inc. Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
CN115974647B (zh) * 2022-12-05 2024-09-03 江苏宏邦化工科技有限公司 以四氢-4-甲基-2-苯基-2h-吡喃-4-醇为原料制备苯乐戊醇的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187371B1 (en) 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
JPH07277979A (ja) * 1994-04-12 1995-10-24 Asahi Chem Ind Co Ltd 過粘性症候群治療または予防剤
ATE506967T1 (de) 1999-04-27 2011-05-15 Mitsubishi Tanabe Pharma Corp Arzneimittel zur präventiven oder therapeutische behandlung von lebererkrankungen
BR0113170A (pt) * 2000-08-11 2004-01-06 Purdue Research Foundation Processo para a preparação de dinapsolina
AU2002326823B2 (en) * 2001-09-06 2005-12-15 Merck Sharp & Dohme Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
EP1470121B1 (en) * 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
RS51139B (sr) * 2005-06-28 2010-10-31 Sanofi-Aventis Derivati izohinolina kao inhibitori rho-kinaze
MX2008001053A (es) 2005-07-26 2008-03-19 Sanofi Aventis Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa.
PT1912949E (pt) 2005-07-26 2011-11-23 Sanofi Sa Derivados de ciclo-hexilamina isoquinolona como inibidores da rho-cinase
US7867999B1 (en) * 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
DK2102164T3 (da) 2006-12-27 2011-03-21 Sanofi Aventis Cycloalkylaminsubstituerede isochinolin- og isochinolinonderivater
MX2009005862A (es) * 2006-12-27 2009-06-17 Sanofi Aventis Nuevos derivados de isoquinolina e isoquinolinona sustituidos.
KR20090094338A (ko) 2006-12-27 2009-09-04 사노피-아벤티스 치환된 이소퀴놀린 및 이소퀴놀리논 유도체
JP5421783B2 (ja) 2006-12-27 2014-02-19 サノフイ Rhoキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体
MX2009005964A (es) 2006-12-27 2009-06-15 Sanofi Aventis Derivados de isoquinolina sustituidos con cicloalquilamina.
ES2364511T3 (es) 2006-12-27 2011-09-05 Sanofi Derivados de isoquinolona e isoquinolinona sustituidos con cicloalquilamina.
TW200845988A (en) * 2007-04-05 2008-12-01 Astrazeneca Ab New compounds and their uses 707
BRPI0914330A2 (pt) 2008-06-24 2019-09-24 Sanofi Aventis derivados de isoquinolina e isoquinolinona substituídos bl-e policíclicos
PL2313374T3 (pl) 2008-06-24 2014-03-31 Sanofi Sa 6-podstawione izochinoliny i izochinolinony
US8541449B2 (en) 2008-06-24 2013-09-24 Sanofi Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors

Also Published As

Publication number Publication date
WO2015124877A1 (fr) 2015-08-27
ME02863B (me) 2018-04-20
SG11201605662TA (en) 2016-08-30
AR099493A1 (es) 2016-07-27
LT3107900T (lt) 2017-12-27
PT3107900T (pt) 2018-01-08
JP2017506251A (ja) 2017-03-02
CY1120034T1 (el) 2018-12-12
RS56766B1 (sr) 2018-04-30
JO3372B1 (ar) 2019-03-13
EP3107900B1 (fr) 2017-11-15
HK1232220A1 (zh) 2018-01-05
AU2015220659A1 (en) 2016-08-04
DK3107900T3 (en) 2018-02-19
MY178745A (en) 2020-10-20
KR102251198B1 (ko) 2021-05-11
CL2016002089A1 (es) 2017-01-27
EP3107900A1 (fr) 2016-12-28
US9809553B2 (en) 2017-11-07
NZ722513A (en) 2019-08-30
ES2659885T3 (es) 2018-03-19
US20170137385A1 (en) 2017-05-18
EA201691675A1 (ru) 2017-02-28
UY35997A (es) 2015-08-31
EA030617B1 (ru) 2018-08-31
FR3017868A1 (fr) 2015-08-28
UA117953C2 (uk) 2018-10-25
PL3107900T3 (pl) 2018-04-30
MA39207A1 (fr) 2017-04-28
ZA201604976B (en) 2022-05-25
RU2679621C2 (ru) 2019-02-12
TW201534587A (zh) 2015-09-16
IL246721B (en) 2018-12-31
KR20160116003A (ko) 2016-10-06
MX2016010779A (es) 2016-10-26
TWI547484B (zh) 2016-09-01
HUE038337T2 (hu) 2018-10-29
SI3107900T1 (en) 2018-02-28
AU2015220659B2 (en) 2018-09-13
MX363301B (es) 2019-03-20
CN105980361A (zh) 2016-09-28
NO3107900T3 (cg-RX-API-DMAC7.html) 2018-04-14
CN105980361B (zh) 2019-05-21
RU2016137502A (ru) 2018-03-27
CA2938344C (fr) 2018-07-03
JP6491226B2 (ja) 2019-03-27
BR112016017679B1 (pt) 2022-07-26
RU2016137502A3 (cg-RX-API-DMAC7.html) 2018-09-24
BR112016017679A2 (cg-RX-API-DMAC7.html) 2017-08-08
CA2938344A1 (fr) 2015-08-27

Similar Documents

Publication Publication Date Title
HRP20180141T1 (hr) 5-benzilizokinolinski derivati za liječenje srčanožilnih bolesti
US8039493B2 (en) Biaryl sulfonamide derivatives
TWI355383B (en) Process for the manufacture of dihydropteridinones
JP5187901B2 (ja) ヒドラジンアミド誘導体
JP4928446B2 (ja) 置換されたテトラヒドロ−2h−イソキノリン−1−オン誘導体、その製造方法及び薬剤としてのその使用
JP2562503B2 (ja) プロペノンオキシムエーテル類、その製造方法、並びにこれを含有する調剤組成物
KR20180087413A (ko) 개선된 인도시아닌 그린의 제조방법
HU224354B1 (hu) 2-Aminoindán-származékok alkalmazása és az ezeket tartalmazó gyógyszerkészítmények
CN101282926B (zh) S1p3受体拮抗剂
JP2004269469A (ja) ピリミジン誘導体又はその塩
CN105622546B (zh) 沃替西汀的一种制备方法
CN110713443A (zh) 制备丙二腈肟醚类化合物的方法及中间体化合物
KR20110013498A (ko) 3,6-디히드로-1,3,5-트리아진 유도체의 제조방법
JPWO2002057216A1 (ja) 置換アミノ基を有するテルフェニル化合物
RU2557236C2 (ru) Способ получения соединений 2-(1-фенилэтил)изоиндолин-1-она
JPH07267954A (ja) 新規の3−フェニルスルホニル−3,7−ジアザビシクロ[3,3,1ノナン−化合物、その製法及び抗不整脈剤
JP2020503334A (ja) ピリミジン化合物
BR112019017309A2 (pt) Protodescarboxilação catalisada por metal de transição de derivados de ácido alfa-halo-acrílico
WO2017016523A1 (zh) 靶向idh2突变的抗肿瘤化合物及其使用方法
US20020026065A1 (en) 2-hydroxy-3 - (4-hydroxy-3-sulfonamidophenyl) - propylamines useful as beta 3 adrenergic agonists
WO2017161555A1 (zh) 用于合成被芳基或杂芳基取代的5-羟基-1,7-萘啶化合物的中间体及其制备方法
US8552197B2 (en) Sorafenib ethylsulfonate salt, process for preparation and use
CN102382076B (zh) 芳酮和芳酰胺类化合物及其制法和药物用途
WO2015192774A1 (zh) 手性氨基酚配体在依法韦仑不对称合成中的应用
JPWO2019088057A1 (ja) アニリド誘導体及びその医薬用途